Ebola virus (EBOV;also known as Zaire ebolavirus) (family Filoviridae) is among the most lethal infectious agents known, producing sporadic outbreaks of severe, and highly lethal hemorrhagic fever in humans and nonhuman primates (NHPs). Owing to high morbidity and mortality rates in natural outbreaks, lack of prophylactic and treatment options, aerosol transmission potential, and their highly virulent nature, Ebola viruses have been identified as both NIAID Category A Priority pathogens and CDC Category A Agents of Bioterrorism. Despite this, the current standard of care is limited to palliative treatment and no therapeutic interventions have been approved against EBOV infection. Among many prophylactic and therapeutic platforms currently under development, monoclonal antibody (mAb) technology has emerged as one ofthe most promising treatment methods. Worldwide, there exist ~100 mAbs against EBOV that have been characterized to varying degrees. Six of these mAbs have demonstrated complete to partial protection of NHPs when administered from 1 to 4- 5 days after lethal infection. The goal of Project 1 is to achieve total protection in NHPs as late as possible in the course of infection with an

Public Health Relevance

This project will translate necessary post-exposure antibody cocktails against Ebola virus (Zaire): immediately from a small, fast-tracked antibody pool, and later from an unprecedented, field-wide, definitive analysis of a pool of almost all antibodies known against Ebola virus.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-LR-M (J1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Scripps Research Institute
La Jolla
United States
Zip Code
Saphire, Erica Ollmann; Schendel, Sharon L; Fusco, Marnie L et al. (2018) Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection. Cell 174:938-952.e13
Siragam, Vinayakumar; Wong, Gary; Qiu, Xiang-Guo (2018) Animal models for filovirus infections. Zool Res 39:15-24
West, Brandyn R; Moyer, Crystal L; King, Liam B et al. (2018) Structural Basis of Pan-Ebolavirus Neutralization by a Human Antibody against a Conserved, yet Cryptic Epitope. MBio 9:
Gilchuk, Pavlo; Mire, Chad E; Geisbert, Joan B et al. (2018) Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates. J Infect Dis 218:S565-S573
Yang, Shu; Xu, Miao; Lee, Emily M et al. (2018) Emetine inhibits Zika and Ebola virus infections through two molecular mechanisms: inhibiting viral replication and decreasing viral entry. Cell Discov 4:31
Gilchuk, Pavlo; Kuzmina, Natalia; Ilinykh, Philipp A et al. (2018) Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein. Immunity 49:363-374.e10
Nyakatura, Elisabeth K; Zak, Samantha E; Wec, Anna Z et al. (2018) Design and evaluation of bi- and trispecific antibodies targeting multiple filovirus glycoproteins. J Biol Chem 293:6201-6211
Zhu, Wenjun; Zhang, Zirui; He, Shihua et al. (2018) Successful treatment of Marburg virus with orally administrated T-705 (Favipiravir) in a mouse model. Antiviral Res 151:39-49
Wong, Gary; Mendoza, Emelissa J; Plummer, Francis A et al. (2018) From bench to almost bedside: the long road to a licensed Ebola virus vaccine. Expert Opin Biol Ther 18:159-173
Wong, Gary; Qiu, Xiangguo (2018) Funding vaccines for emerging infectious diseases. Hum Vaccin Immunother 14:1760-1762

Showing the most recent 10 out of 62 publications